KALAMAZOO, Mich.--(BUSINESS WIRE)--AureoGen Biosciences, Inc., a Kalamazoo-based biotech company that is using an innovative genetic engineering technology for the discovery and production of novel antibiotics, has announced that it has entered into a license agreement with Takara Bio Inc. The agreement will provide AureoGen access to several patent protected antibiotic compounds, as well as a proprietary organism that produces a potent antifungal compound.
